Avondale Wealth Management’s ARK Genomic Revolution ETF ARKG Stock Holding History

Avondale Wealth Management’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,692	Closed	-$55.5K	–	123
2023 Q4	$55.5K	Sell	1,692 -5,481	-76%	-$149K	0.04%	78
2023 Q3	$200K	Hold	7,173	–	–	0.18%	45
2023 Q2	$245K	Buy	7,173 +1,500	+26%	+$47.1K	0.21%	44
2023 Q1	$171K	Buy	5,673 +1,000	+21%	+$31K	0.15%	47
2022 Q4	$132K	Hold	4,673	–	–	0.11%	43
2022 Q3	$154K	Hold	4,673	–	–	0.17%	39
2022 Q2	$147K	Buy	4,673 +2,500	+115%	+$87.4K	0.17%	40
2022 Q1	$100K	Hold	2,173	–	–	0.12%	50
2021 Q4	$133K	Hold	2,173	–	–	0.13%	49
2021 Q3	$162K	Sell	2,173 -1,000	-32%	-$83.9K	0.16%	49
2021 Q2	$294K	Buy	3,173 +1,132	+55%	+$96.2K	0.27%	39
2021 Q1	$181K	Buy	+2,041	New	+$202K	0.18%	43

Other funds holding ARKG

MMEA

Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Avondale Wealth Management's ARKG Position: Q1 2024 in Review

Avondale Wealth Management sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2024, closing a stake of 1,692 shares — an estimated $55.5K sold.

Avondale Wealth Management first reported a position in ARKG in Q1 2021 and held it in 12 quarters. The position peaked at $294K in Q2 2021. 284 funds tracked by Wall St. Rank hold ARKG as of Q1 2024.

Avondale Wealth Management reported no remaining ARK Genomic Revolution ETF position as of Q1 2024 after selling out during the quarter.
Avondale Wealth Management sold 1,692 ARK Genomic Revolution ETF shares in Q1 2024, an estimated $55.5K.
Avondale Wealth Management first reported a position in ARK Genomic Revolution ETF in Q1 2021 and held it in 12 quarters.
Avondale Wealth Management's ARK Genomic Revolution ETF position peaked at $294K in Q2 2021.
284 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2024.

Based on Avondale Wealth Management's 13F filing for Q1 2024, filed 2 Apr 2024.